Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Marek

Showing results (131-140 of 144) with videos related to

Pageof 15
Sort By:
Acta Neuropathologica|March 30, 2016
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative studyJu-Hee Kang, Brit Mollenhauer, Christopher S Coffey, et al.
The Lancet. Neurology|April 14, 2023
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional studyAndrew Siderowf, Luis Concha-Marambio, David-Erick Lafontant, et al.
The Lancet. Neurology|January 24, 2024
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for researchTanya Simuni, Lana M Chahine, Kathleen Poston, et al.
NPJ Parkinson'S Disease|September 27, 2024
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.
Medrxiv : the Preprint Server for Health Sciences|September 24, 2024
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 28, 2026
Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha-Synuclein Seed Amplification AssaySarah M Brooker, Jacopo Pasquini, Seung Ho Choi, et al.
NPJ Parkinson'S Disease|November 20, 2024
Accelerating Parkinson's Disease drug development with federated learning approachesAmit Khanna, Jamie Adams, Chrystalina Antoniades, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2022
<sup>18</sup>F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear PalsyKonstantin Messerschmidt, Henryk Barthel, Matthias Brendel, et al.
Annals of Neurology|April 21, 2026
Partnering With Participant Advisors on the Parkinson's Progression Markers InitiativeMaggie McGuire Kuhl, Christina Destro, Roseanne D Dobkin, et al.
Trials|October 6, 2022
Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trialCharity G Patterson, Elizabeth Joslin, Alexandra B Gil, et al.
Pageof 15

Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Acta Neuropathologica|March 30, 2016
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative studyJu-Hee Kang, Brit Mollenhauer, Christopher S Coffey, et al.
The Lancet. Neurology|April 14, 2023
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional studyAndrew Siderowf, Luis Concha-Marambio, David-Erick Lafontant, et al.
The Lancet. Neurology|January 24, 2024
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for researchTanya Simuni, Lana M Chahine, Kathleen Poston, et al.
NPJ Parkinson'S Disease|September 27, 2024
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.
Medrxiv : the Preprint Server for Health Sciences|September 24, 2024
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 28, 2026
Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha-Synuclein Seed Amplification AssaySarah M Brooker, Jacopo Pasquini, Seung Ho Choi, et al.
NPJ Parkinson'S Disease|November 20, 2024
Accelerating Parkinson's Disease drug development with federated learning approachesAmit Khanna, Jamie Adams, Chrystalina Antoniades, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2022
<sup>18</sup>F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear PalsyKonstantin Messerschmidt, Henryk Barthel, Matthias Brendel, et al.
Annals of Neurology|April 21, 2026
Partnering With Participant Advisors on the Parkinson's Progression Markers InitiativeMaggie McGuire Kuhl, Christina Destro, Roseanne D Dobkin, et al.
Trials|October 6, 2022
Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trialCharity G Patterson, Elizabeth Joslin, Alexandra B Gil, et al.
Pageof 15